EU CTR stands for European Union Clinical Trials Regulation. This regulation, officially known as Regulation (EU) No 536/2014, governs the conduct of clinical trials on medicinal products for human use within the European Union.
The EU CTR aims to harmonize the assessment and supervision processes for clinical trials throughout the EU. It establishes a centralized EU portal and database for clinical trials, streamlining the application process and enhancing transparency in clinical research across member states.
The EU CTR is crucial in clinical research as it standardizes and simplifies the clinical trial application process across the European Union. This harmonization reduces administrative burden, accelerates trial approvals, and promotes collaboration among member states, ultimately speeding up the development of new treatments.
Furthermore, the EU CTR enhances transparency and public access to clinical trial information through its centralized database. This increased transparency fosters greater public trust in clinical research, encourages participant enrollment, and facilitates knowledge sharing among researchers, potentially leading to more efficient and effective clinical studies.
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Copyright @ 2026 Axcellant